摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Acetyl-9-methyl-7H-furo[3,2-g][1]benzopyran-7-one | 114460-34-3

中文名称
——
中文别名
——
英文名称
2-Acetyl-9-methyl-7H-furo[3,2-g][1]benzopyran-7-one
英文别名
2-acetyl-9-methylfuro[3,2-g]chromen-7-one
2-Acetyl-9-methyl-7H-furo[3,2-g][1]benzopyran-7-one化学式
CAS
114460-34-3
化学式
C14H10O4
mdl
——
分子量
242.23
InChiKey
UBAQOMNVOJXBKF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    56.5
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • Drug delivery system for hydrophobic drugs
    申请人:QLT, Inc.
    公开号:EP1900357A2
    公开(公告)日:2008-03-19
    Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.
    本文介绍了由含有疏水性药物的微团聚体组成的组合物及其生产方法。这种微团聚体可包括胶束结构或其与脂质体的组合,并构成疏水性药物的有效递送载体。微团聚体的生产方法包括使用优选的脂质化合物和有利于生产小团聚体的加工条件,以提高过滤灭菌效果。
  • Immuno-adjuvant PDT treatment of metastatic tumors
    申请人:——
    公开号:US20020022032A1
    公开(公告)日:2002-02-21
    Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells.
    治疗和预防转移性癌症的免疫辅助光动力疗法是利用光敏剂与免疫辅助剂相结合来破坏转移性肿瘤细胞。
  • Supports for photosensitizer formulations
    申请人:——
    公开号:US20020061330A1
    公开(公告)日:2002-05-23
    The invention is generally related to the field of formulating medicaments in association with a solid support. Such formulations comprising photosensitizers, and their use in photodynamic therapy, are also provided. Methods for the production of the medicament formulations are also disclosed.
    本发明一般涉及与固体支持物结合的药物制剂领域。本发明还提供了包含光敏剂的此类制剂及其在光动力疗法中的应用。本发明还公开了药物制剂的生产方法。
  • Drug delivery systems for photodynamic therapy
    申请人:——
    公开号:US20020155089A1
    公开(公告)日:2002-10-24
    The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.
    本发明一般涉及光动力疗法领域,使用光敏剂和光敏剂的稳定制剂。这些制剂可用于将光敏剂作为药物、农业或工业制剂输送。本发明含有光敏剂的制剂和组合物包括一种或多种嵌段共聚物。此外,本发明还涉及生产和应用上述制剂和组合物作为光敏剂给药系统的工艺。
  • Method to prevent vision loss
    申请人:——
    公开号:US20020183302A1
    公开(公告)日:2002-12-05
    An improved method to treat conditions of the eye characterized by ocular neovascularization is provided in which patients are given and initial photodynamic therapy (PDT) treatment to destroy the neovasculature, and then are re-evaluated at least twice during the following 6 months, and retreated as necessary. Preferably, three retreatments are provided.
    本研究提供了一种治疗以眼部新生血管为特征的眼部疾病的改进方法,该方法对患者进行初始光动力疗法(PDT)治疗,以破坏新生血管,然后在随后的 6 个月内对患者进行至少两次重新评估,并在必要时进行再治疗。最好进行三次再治疗。
查看更多